Immunoglobulins Market: Global Industry Analysis and Forecast (2022-2029)


Immunoglobulins Market is expected to reach US$ 20.59 Bn. at a CAGR of 6.6% during the forecast period 2029.

Immunoglobulins Market

To know about the Research Methodology :- Request Free Sample Report

The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

Immunoglobulins are glycoproteins made in the response to an immunogen by plasma cells and purpose as antibodies. Overall purposes of immunoglobulins are antigen binding and effector functions. Immunoglobulins bind exactly to antigenic determinants and prevent the host from infections.

The report contains a detailed list of factors that will drive and growth and restraint of the immunoglobulin’s market. Manufacturers are more focused on innovations to upsurge the applicability of immunoglobulins in other indications. Biotechnology companies work closely with research organizations and academic institutes for the development of immunoglobulins by alternative means. In Developed economies, demand for immunoglobulins is increasing because of high awareness and others part of the market, manufacturers are mainly focused on marketing to increase awareness among the end-user. Immunoglobulins market have a presence of many regional players which have a huge market share in emerging countries operating at the regional or country level.

However, stringent government regulations related to immunoglobulin products and high risk of side effects, on the consumption of immunoglobulin are other factors hindering the growth of the global immunoglobulins market to a certain extent.

The report offers a brief analysis of the major regions in the immunoglobulins market, namely, Asia-Pacific, Europe, North America, South America, and the Middle East & Africa. The North America immunoglobulins market was worth USD xx Mn in 2021. Immunoglobulin is the most popular treatment available for many immune disorders. Additionally, the number of patients in the region is growing. These factors are expected to contribute to market growth.

The intravenous segment accounted for the highest revenue in 2021 and expected to maintain its dominance during the forecast period. High bioavailability of immunoglobulins and rapid absorption rate existing by intravenous mode of delivery are the factors that supplement the growth of the intravenous mode of delivery immunoglobulins market globally.

The report offers a recent development in the global market for immunoglobulins like in 2017 Grifols, S.A was prominent the global immunoglobulins market. Grifols owns a diverse product portfolio and that is aiding the organization to have major gains. The company holds a major share in many regional markets also.

The objective of the report is to present comprehensive analysis of Global Immunoglobulins Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Immunoglobulins Market dynamics, structure by analyzing the market segments, and project the Global Immunoglobulins Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Immunoglobulins Market make the report investor’s guide.

Immunoglobulins Market Scope: Inquire before buying


Immunoglobulins Market, By Application

• Hypogammaglobulinemia
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Immunodeficiency Disease
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• Idiopathic Thrombocytopenic Purpura (ITP)
• Inflammatory Myopathies
• Specific Antibody Deficiency
• Guillain‐Barré Syndrome
• Others

Immunoglobulins Market, By Product

• IgG
• IgA
• IgM
• IgE
• IgD

Immunoglobulins Market, By Mode of Delivery

• Intravenous
o 5% Concentration
o 10% Concentration
o Others
• Subcutaneous
o 16.5% Concentration
o 20% Concentration
o Others

Immunoglobulins Market, by Region

• North America
• Asia Pacific
• Europe
• Middle East & Africa
• South America

Immunoglobulins Market Key players

• Shire (Takeda Pharmaceutical Company Limited)
• CSL Behring
• Grifols, S.A.
• Kedrion S.p.A
• Octapharma
• Bio Products Laboratory Ltd.
• Biotest AG
• China Biologic Products Holdings, Inc.
• LFB SA
• Shanghai RAAS Blood Products Co., Ltd.
• Amgen Inc
• AbbVie Inc.
• Gilead Sciences
• Novartis AG
• Johnson & Johnson
• Merck & Co., Inc
• F. Hoffmann-La Roche Ltd
• Baxter International Inc.
• Sanquin
• Bayer Ag

Frequently Asked Questions:

1. Which region has the largest share in Global Immunoglobulins Market?
Ans: North America region holds the highest share in 2021.

2. What is the growth rate of Global Immunoglobulins Market?
Ans: The Global Immunoglobulins Market is growing at a CAGR of 6.6% during forecasting period 2022-2029.

3. What is scope of the Global Immunoglobulins market report?
Ans: Global Immunoglobulins Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Immunoglobulins market?
Ans: The important key players in the Global Immunoglobulins Market are – Shire (Takeda Pharmaceutical Company Limited), CSL Behring, Grifols, S.A., Kedrion S.p.A, Octapharma, Bio Products Laboratory Ltd., Biotest AG, China Biologic Products Holdings, Inc., LFB SA, Shanghai RAAS Blood Products Co., Ltd., Amgen Inc, AbbVie Inc., Gilead Sciences, Novartis AG, Johnson & Johnson, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Baxter International Inc., Sanquin, and Bayer Ag

5. What is the study period of this market?
Ans: The Global Immunoglobulins Market is studied from 2021 to 2029. 




Global Immunoglobulins Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Immunoglobulins Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators
6. Global Immunoglobulins Market Analysis and Forecast
6.1. Global Immunoglobulins Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Immunoglobulins Market Analysis and Forecast, By Application
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Immunoglobulins Market Value Share Analysis, By Application
7.4. Global Immunoglobulins Market Size (US$ Bn) Forecast, By Application
7.5. Global Immunoglobulins Market Analysis, By Application
7.6. Global Immunoglobulins Market Attractiveness Analysis, By Application

8. Global Immunoglobulins Market Analysis and Forecast, By Product
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Immunoglobulins Market Value Share Analysis, By Product
8.4. Global Immunoglobulins Market Size (US$ Bn) Forecast, By Product
8.5. Global Immunoglobulins Market Analysis, By Product
8.6. Global Immunoglobulins Market Attractiveness Analysis, By Product

9. Global Immunoglobulins Market Analysis and Forecast, By Mode of Delivery
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Immunoglobulins Market Value Share Analysis, By Mode of Delivery
9.4. Global Immunoglobulins Market Size (US$ Bn) Forecast, By Mode of Delivery
9.5. Global Immunoglobulins Market Analysis, By Mode of Delivery
9.6. Global Immunoglobulins Market Attractiveness Analysis, By Mode of Delivery

10. Global Immunoglobulins Market Analysis, by Region
10.1. Global Immunoglobulins Market Value Share Analysis, by Region
10.2. Global Immunoglobulins Market Size (US$ Bn) Forecast, by Region
10.3. Global Immunoglobulins Market Attractiveness Analysis, by Region

11. North America Immunoglobulins Market Analysis
11.1. Key Findings
11.2. North America Immunoglobulins Market Overview
11.3. North America Immunoglobulins Market Value Share Analysis, By Application
11.4. North America Immunoglobulins Market Forecast, By Application
11.4.1. Hypogammaglobulinemia
11.4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.4.3. Immunodeficiency Disease
11.4.4. Myasthenia Gravis
11.4.5. Multifocal Motor Neuropathy
11.4.6. Idiopathic Thrombocytopenic Purpura (ITP)
11.4.7. Inflammatory Myopathies
11.4.8. Specific Antibody Deficiency
11.4.9. Guillain-Barré Syndrome
11.4.10. Others
11.5. North America Immunoglobulins Market Value Share Analysis, By Product
11.6. North America Immunoglobulins Market Forecast, By Product
11.6.1. IgG
11.6.2. IgA
11.6.3. IgM
11.6.4. IgE
11.6.5. IgD
11.7. North America Immunoglobulins Market Value Share Analysis, By Mode of Delivery
11.8. North America Immunoglobulins Market Forecast, By Mode of Delivery
11.8.1. Intravenous
11.8.1.1. 5% Concentration
11.8.1.2. 10% Concentration
11.8.1.3. Others
11.8.2. Subcutaneous
11.8.2.1. 16.5% Concentration
11.8.2.2. 20% Concentration
11.8.2.3. Others
11.9. North America Immunoglobulins Market Value Share Analysis, by Country
11.10. North America Immunoglobulins Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Immunoglobulins Market Analysis, by Country
11.12. U.S. Immunoglobulins Market Forecast, By Application
11.12.1. Hypogammaglobulinemia
11.12.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.12.3. Immunodeficiency Disease
11.12.4. Myasthenia Gravis
11.12.5. Multifocal Motor Neuropathy
11.12.6. Idiopathic Thrombocytopenic Purpura (ITP)
11.12.7. Inflammatory Myopathies
11.12.8. Specific Antibody Deficiency
11.12.9. Guillain-Barré Syndrome
11.12.10. Others
11.13. U.S. Immunoglobulins Market Forecast, By Product
11.13.1. IgG
11.13.2. IgA
11.13.3. IgM
11.13.4. IgE
11.13.5. IgD
11.14. U.S. Immunoglobulins Market Forecast, By Mode of Delivery
11.14.1. Intravenous
11.14.1.1. 5% Concentration
11.14.1.2. 10% Concentration
11.14.1.3. Others
11.14.2. Subcutaneous
11.14.2.1. 16.5% Concentration
11.14.2.2. 20% Concentration
11.14.2.3. Others
11.15. Canada Immunoglobulins Market Forecast, By Application
11.15.1. Hypogammaglobulinemia
11.15.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.15.3. Immunodeficiency Disease
11.15.4. Myasthenia Gravis
11.15.5. Multifocal Motor Neuropathy
11.15.6. Idiopathic Thrombocytopenic Purpura (ITP)
11.15.7. Inflammatory Myopathies
11.15.8. Specific Antibody Deficiency
11.15.9. Guillain-Barré Syndrome
11.15.10. Others
11.16. Steel Canada Immunoglobulins Market Forecast, By Product
11.16.1. IgG
11.16.2. IgA
11.16.3. IgM
11.16.4. IgE
11.16.5. IgD
11.17. Canada Immunoglobulins Market Forecast, By Mode of Delivery
11.17.1. Intravenous
11.17.1.1. 5% Concentration
11.17.1.2. 10% Concentration
11.17.1.3. Others
11.17.2. Subcutaneous
11.17.2.1. 16.5% Concentration
11.17.2.2. 20% Concentration
11.17.2.3. Others
11.18. North America Immunoglobulins Market Attractiveness Analysis
11.18.1. By Application
11.18.2. By Product
11.18.3. By Mode of Delivery
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments

12. Europe Immunoglobulins Market Analysis
12.1. Key Findings
12.2. Europe Immunoglobulins Market Overview
12.3. Europe Immunoglobulins Market Value Share Analysis, By Application
12.4. Europe Immunoglobulins Market Forecast, By Application
12.4.1. Hypogammaglobulinemia
12.4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.4.3. Immunodeficiency Disease
12.4.4. Myasthenia Gravis
12.4.5. Multifocal Motor Neuropathy
12.4.6. Idiopathic Thrombocytopenic Purpura (ITP)
12.4.7. Inflammatory Myopathies
12.4.8. Specific Antibody Deficiency
12.4.9. Guillain-Barré Syndrome
12.4.10. Others
12.5. Europe Immunoglobulins Market Value Share Analysis, By Product
12.6. Europe Immunoglobulins Market Forecast, By Product
12.6.1. IgG
12.6.2. IgA
12.6.3. IgM
12.6.4. IgE
12.6.5. IgD
12.7. Europe Immunoglobulins Market Value Share Analysis, By Mode of Delivery
12.8. Europe Immunoglobulins Market Forecast, By Mode of Delivery
12.8.1. Intravenous
12.8.1.1. 5% Concentration
12.8.1.2. 10% Concentration
12.8.1.3. Others
12.8.2. Subcutaneous
12.8.2.1. 16.5% Concentration
12.8.2.2. 20% Concentration
12.8.2.3. Others
12.9. Europe Immunoglobulins Market Value Share Analysis, by Country
12.10. Europe Immunoglobulins Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Immunoglobulins Market Analysis, by Country
12.12. Germany Immunoglobulins Market Forecast, By Application
12.12.1. Hypogammaglobulinemia
12.12.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.12.3. Immunodeficiency Disease
12.12.4. Myasthenia Gravis
12.12.5. Multifocal Motor Neuropathy
12.12.6. Idiopathic Thrombocytopenic Purpura (ITP)
12.12.7. Inflammatory Myopathies
12.12.8. Specific Antibody Deficiency
12.12.9. Guillain-Barré Syndrome
12.12.10. Others
12.13. Germany Immunoglobulins Market Forecast, By Product
12.13.1. IgG
12.13.2. IgA
12.13.3. IgM
12.13.4. IgE
12.13.5. IgD
12.14. Germany Immunoglobulins Market Forecast, By Mode of Delivery
12.14.1. Intravenous
12.14.1.1. 5% Concentration
12.14.1.2. 10% Concentration
12.14.1.3. Others
12.14.2. Subcutaneous
12.14.2.1. 16.5% Concentration
12.14.2.2. 20% Concentration
12.14.2.3. Others
12.15. U.K. Immunoglobulins Market Forecast, By Application
12.15.1. Hypogammaglobulinemia
12.15.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.15.3. Immunodeficiency Disease
12.15.4. Myasthenia Gravis
12.15.5. Multifocal Motor Neuropathy
12.15.6. Idiopathic Thrombocytopenic Purpura (ITP)
12.15.7. Inflammatory Myopathies
12.15.8. Specific Antibody Deficiency
12.15.9. Guillain-Barré Syndrome
12.15.10. Others
12.16. U.K. Immunoglobulins Market Forecast, By Product
12.16.1. IgG
12.16.2. IgA
12.16.3. IgM
12.16.4. IgE
12.16.5. IgD
12.17. U.K. Immunoglobulins Market Forecast, By Mode of Delivery
12.17.1. Intravenous
12.17.1.1. 5% Concentration
12.17.1.2. 10% Concentration
12.17.1.3. Others
12.17.2. Subcutaneous
12.17.2.1. 16.5% Concentration
12.17.2.2. 20% Concentration
12.17.2.3. Others
12.18. France Immunoglobulins Market Forecast, By Application
12.18.1. Hypogammaglobulinemia
12.18.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.18.3. Immunodeficiency Disease
12.18.4. Myasthenia Gravis
12.18.5. Multifocal Motor Neuropathy
12.18.6. Idiopathic Thrombocytopenic Purpura (ITP)
12.18.7. Inflammatory Myopathies
12.18.8. Specific Antibody Deficiency
12.18.9. Guillain-Barré Syndrome
12.18.10. Others
12.19. France Immunoglobulins Market Forecast, By Product
12.19.1. IgG
12.19.2. IgA
12.19.3. IgM
12.19.4. IgE
12.19.5. IgD
12.20. France Immunoglobulins Market Forecast, By Mode of Delivery
12.20.1. Intravenous
12.20.1.1. 5% Concentration
12.20.1.2. 10% Concentration
12.20.1.3. Others
12.20.2. Subcutaneous
12.20.2.1. 16.5% Concentration
12.20.2.2. 20% Concentration
12.20.2.3. Others
12.21. Italy Immunoglobulins Market Forecast, By Application
12.21.1. Hypogammaglobulinemia
12.21.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.21.3. Immunodeficiency Disease
12.21.4. Myasthenia Gravis
12.21.5. Multifocal Motor Neuropathy
12.21.6. Idiopathic Thrombocytopenic Purpura (ITP)
12.21.7. Inflammatory Myopathies
12.21.8. Specific Antibody Deficiency
12.21.9. Guillain-Barré Syndrome
12.21.10. Others
12.22. Italy Immunoglobulins Market Forecast, By Product
12.22.1. IgG
12.22.2. IgA
12.22.3. IgM
12.22.4. IgE
12.22.5. IgD
12.23. Italy Immunoglobulins Market Forecast, By Mode of Delivery
12.23.1. Intravenous
12.23.1.1. 5% Concentration
12.23.1.2. 10% Concentration
12.23.1.3. Others
12.23.2. Subcutaneous
12.23.2.1. 16.5% Concentration
12.23.2.2. 20% Concentration
12.23.2.3. Others
12.24. Spain Immunoglobulins Market Forecast, By Application
12.24.1. Hypogammaglobulinemia
12.24.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.24.3. Immunodeficiency Disease
12.24.4. Myasthenia Gravis
12.24.5. Multifocal Motor Neuropathy
12.24.6. Idiopathic Thrombocytopenic Purpura (ITP)
12.24.7. Inflammatory Myopathies
12.24.8. Specific Antibody Deficiency
12.24.9. Guillain-Barré Syndrome
12.24.10. Others
12.25. Spain Immunoglobulins Market Forecast, By Product
12.25.1. IgG
12.25.2. IgA
12.25.3. IgM
12.25.4. IgE
12.25.5. IgD
12.26. Spain Immunoglobulins Market Forecast, By Mode of Delivery
12.26.1. Intravenous
12.26.1.1. 5% Concentration
12.26.1.2. 10% Concentration
12.26.1.3. Others
12.26.2. Subcutaneous
12.26.2.1. 16.5% Concentration
12.26.2.2. 20% Concentration
12.26.2.3. Others
12.27. Rest of Europe Immunoglobulins Market Forecast, By Application
12.27.1. Hypogammaglobulinemia
12.27.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.27.3. Immunodeficiency Disease
12.27.4. Myasthenia Gravis
12.27.5. Multifocal Motor Neuropathy
12.27.6. Idiopathic Thrombocytopenic Purpura (ITP)
12.27.7. Inflammatory Myopathies
12.27.8. Specific Antibody Deficiency
12.27.9. Guillain-Barré Syndrome
12.27.10. Others
12.28. Rest of Europe Immunoglobulins Market Forecast, By Product
12.28.1. IgG
12.28.2. IgA
12.28.3. IgM
12.28.4. IgE
12.28.5. IgD
12.29. Rest Of Europe Immunoglobulins Market Forecast, By Mode of Delivery
12.29.1. Intravenous
12.29.1.1. 5% Concentration
12.29.1.2. 10% Concentration
12.29.1.3. Others
12.29.2. Subcutaneous
12.29.2.1. 16.5% Concentration
12.29.2.2. 20% Concentration
12.29.2.3. Others
12.30. Europe Immunoglobulins Market Attractiveness Analysis
12.30.1. By Application
12.30.2. By Product
12.30.3. By Mode of Delivery
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments

13. Asia Pacific Immunoglobulins Market Analysis
13.1. Key Findings
13.2. Asia Pacific Immunoglobulins Market Overview
13.3. Asia Pacific Immunoglobulins Market Value Share Analysis, By Application
13.4. Asia Pacific Immunoglobulins Market Forecast, By Application
13.4.1. Hypogammaglobulinemia
13.4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.4.3. Immunodeficiency Disease
13.4.4. Myasthenia Gravis
13.4.5. Multifocal Motor Neuropathy
13.4.6. Idiopathic Thrombocytopenic Purpura (ITP)
13.4.7. Inflammatory Myopathies
13.4.8. Specific Antibody Deficiency
13.4.9. Guillain-Barré Syndrome
13.4.10. Others
13.5. Asia Pacific Immunoglobulins Market Value Share Analysis, By Product
13.6. Asia Pacific Immunoglobulins Market Forecast, By Product
13.6.1. IgG
13.6.2. IgA
13.6.3. IgM
13.6.4. IgE
13.6.5. IgD
13.7. Asia Pacific Immunoglobulins Market Value Share Analysis, By Mode of Delivery
13.8. Asia Pacific Immunoglobulins Market Forecast, By Mode of Delivery
13.8.1. Intravenous
13.8.1.1. 5% Concentration
13.8.1.2. 10% Concentration
13.8.1.3. Others
13.8.2. Subcutaneous
13.8.2.1. 16.5% Concentration
13.8.2.2. 20% Concentration
13.8.2.3. Others
13.9. Asia Pacific Immunoglobulins Market Value Share Analysis, by Country
13.10. Asia Pacific Immunoglobulins Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Immunoglobulins Market Analysis, by Country
13.12. China Immunoglobulins Market Forecast, By Application
13.12.1. Hypogammaglobulinemia
13.12.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.12.3. Immunodeficiency Disease
13.12.4. Myasthenia Gravis
13.12.5. Multifocal Motor Neuropathy
13.12.6. Idiopathic Thrombocytopenic Purpura (ITP)
13.12.7. Inflammatory Myopathies
13.12.8. Specific Antibody Deficiency
13.12.9. Guillain-Barré Syndrome
13.12.10. Others
13.13. China Immunoglobulins Market Forecast, By Product
13.13.1. IgG
13.13.2. IgA
13.13.3. IgM
13.13.4. IgE
13.13.5. IgD
13.14. China Immunoglobulins Market Forecast, By Mode of Delivery
13.14.1. Intravenous
13.14.1.1. 5% Concentration
13.14.1.2. 10% Concentration
13.14.1.3. Others
13.14.2. Subcutaneous
13.14.2.1. 16.5% Concentration
13.14.2.2. 20% Concentration
13.14.2.3. Others
13.15. India Immunoglobulins Market Forecast, By Application
13.15.1. Hypogammaglobulinemia
13.15.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.15.3. Immunodeficiency Disease
13.15.4. Myasthenia Gravis
13.15.5. Multifocal Motor Neuropathy
13.15.6. Idiopathic Thrombocytopenic Purpura (ITP)
13.15.7. Inflammatory Myopathies
13.15.8. Specific Antibody Deficiency
13.15.9. Guillain-Barré Syndrome
13.15.10. Others
13.16. India Immunoglobulins Market Forecast, By Product
13.16.1. IgG
13.16.2. IgA
13.16.3. IgM
13.16.4. IgE
13.16.5. IgD
13.17. India Immunoglobulins Market Forecast, By Mode of Delivery
13.17.1. Intravenous
13.17.1.1. 5% Concentration
13.17.1.2. 10% Concentration
13.17.1.3. Others
13.17.2. Subcutaneous
13.17.2.1. 16.5% Concentration
13.17.2.2. 20% Concentration
13.17.2.3. Others
13.18. Japan Immunoglobulins Market Forecast, By Application
13.18.1. Hypogammaglobulinemia
13.18.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.18.3. Immunodeficiency Disease
13.18.4. Myasthenia Gravis
13.18.5. Multifocal Motor Neuropathy
13.18.6. Idiopathic Thrombocytopenic Purpura (ITP)
13.18.7. Inflammatory Myopathies
13.18.8. Specific Antibody Deficiency
13.18.9. Guillain-Barré Syndrome
13.18.10. Others
13.19. Japan Immunoglobulins Market Forecast, By Product
13.19.1. IgG
13.19.2. IgA
13.19.3. IgM
13.19.4. IgE
13.19.5. IgD
13.20. Japan Immunoglobulins Market Forecast, By Mode of Delivery
13.20.1. Intravenous
13.20.1.1. 5% Concentration
13.20.1.2. 10% Concentration
13.20.1.3. Others
13.20.2. Subcutaneous
13.20.2.1. 16.5% Concentration
13.20.2.2. 20% Concentration
13.20.2.3. Others
13.21. ASEAN Immunoglobulins Market Forecast, By Application
13.21.1. Hypogammaglobulinemia
13.21.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.21.3. Immunodeficiency Disease
13.21.4. Myasthenia Gravis
13.21.5. Multifocal Motor Neuropathy
13.21.6. Idiopathic Thrombocytopenic Purpura (ITP)
13.21.7. Inflammatory Myopathies
13.21.8. Specific Antibody Deficiency
13.21.9. Guillain-Barré Syndrome
13.21.10. Others
13.22. ASEAN Immunoglobulins Market Forecast, By Product
13.22.1. IgG
13.22.2. IgA
13.22.3. IgM
13.22.4. IgE
13.22.5. IgD
13.23. ASEAN Immunoglobulins Market Forecast, By Mode of Delivery
13.23.1. Intravenous
13.23.1.1. 5% Concentration
13.23.1.2. 10% Concentration
13.23.1.3. Others
13.23.2. Subcutaneous
13.23.2.1. 16.5% Concentration
13.23.2.2. 20% Concentration
13.23.2.3. Others
13.24. Rest of Asia Pacific Immunoglobulins Market Forecast, By Application
13.24.1. Hypogammaglobulinemia
13.24.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.24.3. Immunodeficiency Disease
13.24.4. Myasthenia Gravis
13.24.5. Multifocal Motor Neuropathy
13.24.6. Idiopathic Thrombocytopenic Purpura (ITP)
13.24.7. Inflammatory Myopathies
13.24.8. Specific Antibody Deficiency
13.24.9. Guillain-Barré Syndrome
13.24.10. Others
13.25. Rest of Asia Pacific Immunoglobulins Market Forecast, By Product
13.25.1. IgG
13.25.2. IgA
13.25.3. IgM
13.25.4. IgE
13.25.5. IgD
13.26. Rest of Asia Pacific Immunoglobulins Market Forecast, By Mode of Delivery
13.26.1. Intravenous
13.26.1.1. 5% Concentration
13.26.1.2. 10% Concentration
13.26.1.3. Others
13.26.2. Subcutaneous
13.26.2.1. 16.5% Concentration
13.26.2.2. 20% Concentration
13.26.2.3. Others
13.27. Asia Pacific Immunoglobulins Market Attractiveness Analysis
13.27.1. By Application
13.27.2. By Product
13.27.3. By Mode of Delivery
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments

14. Middle East & Africa Immunoglobulins Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Immunoglobulins Market Overview
14.3. Middle East & Africa Immunoglobulins Market Value Share Analysis, By Application
14.4. Middle East & Africa Immunoglobulins Market Forecast, By Application
14.4.1. Hypogammaglobulinemia
14.4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
14.4.3. Immunodeficiency Disease
14.4.4. Myasthenia Gravis
14.4.5. Multifocal Motor Neuropathy
14.4.6. Idiopathic Thrombocytopenic Purpura (ITP)
14.4.7. Inflammatory Myopathies
14.4.8. Specific Antibody Deficiency
14.4.9. Guillain-Barré Syndrome
14.4.10. Others
14.5. Middle East & Africa Immunoglobulins Market Value Share Analysis, By Product
14.6. Middle East & Africa Immunoglobulins Market Forecast, By Product
14.6.1. IgG
14.6.2. IgA
14.6.3. IgM
14.6.4. IgE
14.6.5. IgD
14.7. Middle East & Africa Immunoglobulins Market Value Share Analysis, By Mode of Delivery
14.8. Middle East & Africa Immunoglobulins Market Forecast, By Mode of Delivery
14.8.1. Intravenous
14.8.1.1. 5% Concentration
14.8.1.2. 10% Concentration
14.8.1.3. Others
14.8.2. Subcutaneous
14.8.2.1. 16.5% Concentration
14.8.2.2. 20% Concentration
14.8.2.3. Others
14.9. Middle East & Africa Immunoglobulins Market Value Share Analysis, by Country
14.10. Middle East & Africa Immunoglobulins Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Immunoglobulins Market Analysis, by Country
14.12. GCC Immunoglobulins Market Forecast, By Application
14.12.1. Hypogammaglobulinemia
14.12.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
14.12.3. Immunodeficiency Disease
14.12.4. Myasthenia Gravis
14.12.5. Multifocal Motor Neuropathy
14.12.6. Idiopathic Thrombocytopenic Purpura (ITP)
14.12.7. Inflammatory Myopathies
14.12.8. Specific Antibody Deficiency
14.12.9. Guillain-Barré Syndrome
14.12.10. Others
14.13. GCC Immunoglobulins Market Forecast, By Product
14.13.1. IgG
14.13.2. IgA
14.13.3. IgM
14.13.4. IgE
14.13.5. IgD
14.14. GCC Immunoglobulins Market Forecast, By Mode of Delivery
14.14.1. Intravenous
14.14.1.1. 5% Concentration
14.14.1.2. 10% Concentration
14.14.1.3. Others
14.14.2. Subcutaneous
14.14.2.1. 16.5% Concentration
14.14.2.2. 20% Concentration
14.14.2.3. Others
14.15. South Africa Immunoglobulins Market Forecast, By Application
14.15.1. Hypogammaglobulinemia
14.15.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
14.15.3. Immunodeficiency Disease
14.15.4. Myasthenia Gravis
14.15.5. Multifocal Motor Neuropathy
14.15.6. Idiopathic Thrombocytopenic Purpura (ITP)
14.15.7. Inflammatory Myopathies
14.15.8. Specific Antibody Deficiency
14.15.9. Guillain-Barré Syndrome
14.15.10. Others
14.16. South Africa Immunoglobulins Market Forecast, By Product
14.16.1. IgG
14.16.2. IgA
14.16.3. IgM
14.16.4. IgE
14.16.5. IgD
14.17. South Africa Immunoglobulins Market Forecast, By Mode of Delivery
14.17.1. Intravenous
14.17.1.1. 5% Concentration
14.17.1.2. 10% Concentration
14.17.1.3. Others
14.17.2. Subcutaneous
14.17.2.1. 16.5% Concentration
14.17.2.2. 20% Concentration
14.17.2.3. Others
14.18. Rest of Middle East & Africa Immunoglobulins Market Forecast, By Application
14.18.1. Hypogammaglobulinemia
14.18.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
14.18.3. Immunodeficiency Disease
14.18.4. Myasthenia Gravis
14.18.5. Multifocal Motor Neuropathy
14.18.6. Idiopathic Thrombocytopenic Purpura (ITP)
14.18.7. Inflammatory Myopathies
14.18.8. Specific Antibody Deficiency
14.18.9. Guillain-Barré Syndrome
14.18.10. Others
14.19. Rest of Middle East & Africa Immunoglobulins Market Forecast, By Product
14.19.1. IgG
14.19.2. IgA
14.19.3. IgM
14.19.4. IgE
14.19.5. IgD
14.20. Rest of Middle East & Africa Immunoglobulins Market Forecast, By Mode of Delivery
14.20.1. Intravenous
14.20.1.1. 5% Concentration
14.20.1.2. 10% Concentration
14.20.1.3. Others
14.20.2. Subcutaneous
14.20.2.1. 16.5% Concentration
14.20.2.2. 20% Concentration
14.20.2.3. Others
14.21. Middle East & Africa Immunoglobulins Market Attractiveness Analysis
14.21.1. By Application
14.21.2. By Product
14.21.3. By Mode of Delivery
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments

15. South America Immunoglobulins Market Analysis
15.1. Key Findings
15.2. South America Immunoglobulins Market Overview
15.3. South America Immunoglobulins Market Value Share Analysis, By Application
15.4. South America Immunoglobulins Market Forecast, By Application
15.4.1. Hypogammaglobulinemia
15.4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
15.4.3. Immunodeficiency Disease
15.4.4. Myasthenia Gravis
15.4.5. Multifocal Motor Neuropathy
15.4.6. Idiopathic Thrombocytopenic Purpura (ITP)
15.4.7. Inflammatory Myopathies
15.4.8. Specific Antibody Deficiency
15.4.9. Guillain-Barré Syndrome
15.4.10. Others
15.5. South America Immunoglobulins Market Value Share Analysis, By Product
15.6. South America Immunoglobulins Market Forecast, By Product
15.6.1. IgG
15.6.2. IgA
15.6.3. IgM
15.6.4. IgE
15.6.5. IgD
15.7. South America Immunoglobulins Market Value Share Analysis, By Mode of Delivery
15.8. South America Immunoglobulins Market Forecast, By Mode of Delivery
15.8.1. Intravenous
15.8.1.1. 5% Concentration
15.8.1.2. 10% Concentration
15.8.1.3. Others
15.8.2. Subcutaneous
15.8.2.1. 16.5% Concentration
15.8.2.2. 20% Concentration
15.8.2.3. Others

15.9. South America Immunoglobulins Market Value Share Analysis, by Country
15.10. South America Immunoglobulins Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Immunoglobulins Market Analysis, by Country
15.12. Brazil Immunoglobulins Market Forecast, By Application
15.12.1. Hypogammaglobulinemia
15.12.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
15.12.3. Immunodeficiency Disease
15.12.4. Myasthenia Gravis
15.12.5. Multifocal Motor Neuropathy
15.12.6. Idiopathic Thrombocytopenic Purpura (ITP)
15.12.7. Inflammatory Myopathies
15.12.8. Specific Antibody Deficiency
15.12.9. Guillain-Barré Syndrome
15.12.10. Others
15.13. Brazil Immunoglobulins Market Forecast, By Product
15.13.1. IgG
15.13.2. IgA
15.13.3. IgM
15.13.4. IgE
15.13.5. IgD
15.14. Brazil Immunoglobulins Market Forecast, By Mode of Delivery
15.14.1. Intravenous
15.14.1.1. 5% Concentration
15.14.1.2. 10% Concentration
15.14.1.3. Others
15.14.2. Subcutaneous
15.14.2.1. 16.5% Concentration
15.14.2.2. 20% Concentration
15.14.2.3. Others
15.15. Mexico Immunoglobulins Market Forecast, By Application
15.15.1. Hypogammaglobulinemia
15.15.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
15.15.3. Immunodeficiency Disease
15.15.4. Myasthenia Gravis
15.15.5. Multifocal Motor Neuropathy
15.15.6. Idiopathic Thrombocytopenic Purpura (ITP)
15.15.7. Inflammatory Myopathies
15.15.8. Specific Antibody Deficiency
15.15.9. Guillain-Barré Syndrome
15.15.10. Others
15.16. Mexico Immunoglobulins Market Forecast, By Product
15.16.1. IgG
15.16.2. IgA
15.16.3. IgM
15.16.4. IgE
15.16.5. IgD
15.17. Mexico Immunoglobulins Market Forecast, By Mode of Delivery
15.17.1. Intravenous
15.17.1.1. 5% Concentration
15.17.1.2. 10% Concentration
15.17.1.3. Others
15.17.2. Subcutaneous
15.17.2.1. 16.5% Concentration
15.17.2.2. 20% Concentration
15.17.2.3. Others
15.18. Rest of South America Immunoglobulins Market Forecast, By Application
15.18.1. Hypogammaglobulinemia
15.18.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
15.18.3. Immunodeficiency Disease
15.18.4. Myasthenia Gravis
15.18.5. Multifocal Motor Neuropathy
15.18.6. Idiopathic Thrombocytopenic Purpura (ITP)
15.18.7. Inflammatory Myopathies
15.18.8. Specific Antibody Deficiency
15.18.9. Guillain-Barré Syndrome
15.18.10. Others
15.19. Rest of South America Immunoglobulins Market Forecast, By Product
15.19.1. IgG
15.19.2. IgA
15.19.3. IgM
15.19.4. IgE
15.19.5. IgD
15.20. Rest of South America Immunoglobulins Market Forecast, By Mode of Delivery
15.20.1. Intravenous
15.20.1.1. 5% Concentration
15.20.1.2. 10% Concentration
15.20.1.3. Others
15.20.2. Subcutaneous
15.20.2.1. 16.5% Concentration
15.20.2.2. 20% Concentration
15.20.2.3. Others
15.21. South America Immunoglobulins Market Attractiveness Analysis
15.21.1. By Application
15.21.2. By Product
15.21.3. By Mode of Delivery
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Shire (Takeda Pharmaceutical Company Limited)
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. CSL Behring
16.3.3. Grifols, S.A.
16.3.4. Kedrion S.p.A
16.3.5. Octapharma
16.3.6. Bio Products Laboratory Ltd.
16.3.7. Biotest AG
16.3.8. China Biologic Products Holdings, Inc.
16.3.9. LFB SA
16.3.10. Shanghai RAAS Blood Products Co., Ltd.
16.3.11. Amgen Inc
16.3.12. AbbVie Inc.
16.3.13. Gilead Sciences
16.3.14. Novartis AG
16.3.15. Johnson & Johnson
16.3.16. Merck & Co., Inc
16.3.17. F. Hoffmann-La Roche Ltd
16.3.18. Baxter International Inc.
16.3.19. Sanquin
16.3.20. Bayer Ag

17. Primary Key Insights
  • INQUIRE BEFORE BUYING